Latest action: Referred to the House Committee on Energy and Commerce.
Referred to one or more standing committees for review, hearings, and possible markup.
Specific committees not parsed from action data.
The committee may hold hearings, amend the bill, or let it die without action.
Next: Reported
Full chamber floor — Speaker / Majority Leader controls scheduling
Makes it faster for generic copies of expensive biologic drugs to reach patients.
The problem
Biologic drugs are expensive and take years to develop generic versions. Patients wait longer and pay more for medicine than necessary.
The proposal
Streamlines FDA approval process for biosimilar drugs, reducing paperwork and review time to get generic versions to market quicker.
The impact
Patients get cheaper drug options sooner. Drug makers face faster competition. Healthcare costs may decrease for patients and insurers.
Faster biosimilar approval means patients and insurance companies pay less for medication. Generic versions typically cost 30-50% less than original drugs.
More affordable alternatives help uninsured and underinsured patients afford necessary treatments. People can start therapy sooner without financial barriers.
More biosimilars entering the market faster encourages original drug makers to lower prices. Competition drives innovation and better drug options.
Lower drug costs decrease overall healthcare expenses for Medicare, Medicaid, and private insurers. Savings could fund other medical services.
Expedited review might miss problems with generic drugs. Biologic drugs are complex and slight differences can cause harmful side effects.
Faster competition lowers profits for companies developing original biologic drugs. Companies might invest less in research for new treatments.
Fast-tracking approval could allow poorly manufactured drugs to reach patients. Quality problems might not be caught before widespread use.
Original developers invest billions and take decades to create drugs. Faster generic copies reduce their return on investment and market exclusivity.
Generated by AI from the bill text. Not a prediction and not legal or policy advice. The percentage is the model's own rating of each item — self-reported, and not a measure of how accurate it is.
Loading map…
Loading...
0 citizens have already voted
Free · No spam · See how your representatives voted
Be the first to weigh in
Your vote starts the conversation
How citizen engagement works
Citizens vote & comment
Public opinion data is aggregated and updated in real time.
Patterns become visible
Representatives can see constituent sentiment broken down by district.
Your voice on the record
Contact your rep directly — one constituent call can shift a staffer's priority list.
Research shows that constituent contacts — especially calls — are among the most effective ways to influence a legislator's position on active bills.
Individual contributions, grouped by employer · FEC
Where their individual donors work · 2026 cycle
Money from people who work there, not from the company. Not tied to this bill.
Itemized individual contributions via FEC, grouped by the employer each contributor self-reported. Companies and unions cannot contribute to federal candidates from their treasuries, so these totals are money from people who work at an employer — never from the organization itself. They are campaign contributions covering a full election cycle and are not connected to this bill.
Senate LDA lobbying disclosures
Couldn't load lobbying disclosures right now.